RESOURCE LIBRARY

Advancing medicine through scientific ingenuity

RESOURCE LIBRARY

Advancing medicine science through scientific ingenuity

At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.

Filter by

CLEAR
Wednesday, October 29, 2025
8th Annual TPD & Induced Proximity Summit
Degrader Antibody Conjugates (DACs): Targeted Protein Degraders (TPDs) as Next Generation Antibody Drug Conjugate (ADC) Payloads
Wednesday, October 29, 2025
8th Annual TPD & Induced Proximity Summit
Developing a Portfolio of CNS Penetrant Degraders
Tuesday, October 28, 2025
8th Annual TPD & Induced Proximity Summit
Clinical Update on Bexobrutideg: The First ‘-Deg
Saturday, October 18, 2025
European Society for Medical Oncology
First-in-Class CBL-B Inhibitor NX-1607: Phase 1a Data in Patients with Advanced Solid Tumors
Tuesday, September 23, 2025
Discovery on Target
NRX-0305: A Pan-Mutant Brain-Penetrant BRAF Degrader with Broad Preclinical Activity and Synergy with MEKi in Class 1/2/3 BRAF-Mutant Cancers
Wednesday, September 17, 2025
European Academy of Dermatology and Venereology (EADV) Congress
IRAK4 Degrader GS-6791 Inhibits IL-1- and IL-36-Driven Responses in Skin Epithelial Cell Systems and Demonstrates Efficacy in a Mouse Model of Dermatitis
Wednesday, September 3, 2025
SOHO 2025 Annual Meeting
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia
Wednesday, September 3, 2025
SOHO 2025 Annual Meeting
A Phase 1 Trial of Zelebrudomide (NX-2127), a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients with Relapsed/Refractory B-cell Malignancies
Wednesday, September 3, 2025
SOHO 2025 Annual Meeting
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study
Tuesday, July 22, 2025
Bay Area Biotech Day
Rewriting Established Drug Design Rules with a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader